UNIPHARM GRAND OUEST : revenue, balance sheet and financial ratios

UNIPHARM GRAND OUEST is a French company founded 36 years ago, specialized in the sector Centrales d'achat non alimentaires. Based in TOURVILLE-LA-RIVIERE (76410), this company of category PME shows in 2024 a revenue of 3.1 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - UNIPHARM GRAND OUEST (SIREN 377495593)
Indicator 2024 2023 2022 2020 2019 2018 2017 2016
Revenue 3 060 209 € 3 207 039 € 2 629 630 € 3 281 329 € 3 305 823 € 3 164 180 € 3 780 656 € 4 136 119 €
Net income 1 166 918 € 1 319 914 € 618 415 € 1 293 509 € 1 210 923 € 1 223 525 € 1 174 484 € 1 297 678 €
EBITDA 1 222 346 € 1 406 820 € 634 896 € 1 389 875 € 1 299 192 € 1 291 822 € 1 265 580 € 1 437 579 €
Net margin 38.1% 41.2% 23.5% 39.4% 36.6% 38.7% 31.1% 31.4%

Revenue and income statement

In 2024, UNIPHARM GRAND OUEST achieves revenue of 3.1 M€. Activity remains stable over the period (CAGR: -3.7%). Slight decline of -5% vs 2023. After deducting consumption (1.0 M€), gross margin stands at 2.0 M€, i.e. a rate of 66%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.2 M€, representing 39.9% of revenue. Warning negative scissor effect: despite revenue change (-5%), EBITDA varies by -13%, reducing margin by 3.9 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.2 M€, i.e. 38.1% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

3 060 209 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

2 032 021 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

1 222 346 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

1 170 300 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 166 918 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

39.9%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 87%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 38.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.007%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

87.393%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

38.728%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.0

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

71.9%

Solvency indicators evolution
UNIPHARM GRAND OUEST

Sector positioning

Debt ratio
0.01 2024
2022
2023
2024
Q1: 0.09
Med: 12.77
Q3: 91.48
Excellent

In 2024, the debt ratio of UNIPHARM GRAND OUEST (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
87.39% 2024
2022
2023
2024
Q1: 14.45%
Med: 32.5%
Q3: 56.23%
Excellent +13 pts over 3 years

In 2024, the financial autonomy of UNIPHARM GRAND OUEST (87.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.18 years
Q3: 3.44 years
Excellent

In 2024, the repayment capacity of UNIPHARM GRAND OUEST (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 773.14. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.1x. Danger: operating income does not cover interest charges, unsustainable situation.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

773.143

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.113

Liquidity indicators evolution
UNIPHARM GRAND OUEST

Sector positioning

Liquidity ratio
773.14 2024
2022
2023
2024
Q1: 121.61
Med: 177.19
Q3: 308.74
Excellent

In 2024, the liquidity ratio of UNIPHARM GRAND OUEST (773.14) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Interest coverage
0.11x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.78x
Q3: 21.01x
Average -10 pts over 3 years

In 2024, the interest coverage of UNIPHARM GRAND OUEST (0.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 179 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 57 days. The gap of 122 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. Overall, WCR represents 344 days of revenue, i.e. 2.9 M€ to permanently finance.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

2 926 845 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

179 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

57 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

344 j

WCR and payment terms evolution
UNIPHARM GRAND OUEST

Positioning of UNIPHARM GRAND OUEST in its sector

Comparison with sector Centrales d'achat non alimentaires

Valuation estimate

Based on 85 transactions of similar company sales (all years), the value of UNIPHARM GRAND OUEST is estimated at 1 218 591 € (range 648 221€ - 5 013 844€). With an EBITDA of 1 222 346€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.32x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
85 tx
648k€ 1218k€ 5013k€
1 218 591 € Range: 648 221€ - 5 013 844€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
1 222 346 € × 1.0x
Estimation 1 203 100 €
660 462€ - 5 332 121€
Revenue Multiple 30%
3 060 209 € × 0.32x
Estimation 988 641 €
550 641€ - 2 349 274€
Net Income Multiple 20%
1 166 918 € × 1.4x
Estimation 1 602 246 €
763 989€ - 8 215 010€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 85 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Centrales d'achat non alimentaires)

Compare UNIPHARM GRAND OUEST with other companies in the same sector:

Voir toutes les statistiques du secteur Centrales d'achat non alimentaires

Frequently asked questions about UNIPHARM GRAND OUEST

What is the revenue of UNIPHARM GRAND OUEST ?

The revenue of UNIPHARM GRAND OUEST in 2024 is 3.1 M€.

Is UNIPHARM GRAND OUEST profitable?

Yes, UNIPHARM GRAND OUEST generated a net profit of 1.2 M€ in 2024.

Where is the headquarters of UNIPHARM GRAND OUEST ?

The headquarters of UNIPHARM GRAND OUEST is located in TOURVILLE-LA-RIVIERE (76410), in the department Seine-Maritime.

Where to find the tax return of UNIPHARM GRAND OUEST ?

The tax return of UNIPHARM GRAND OUEST is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does UNIPHARM GRAND OUEST operate?

UNIPHARM GRAND OUEST operates in the sector Centrales d'achat non alimentaires (NAF code 46.19A). See the 'Sector positioning' section above to compare the company with its competitors.